Lyra Therapeutics Inc (LYRA) Stock Price, Quote & News

Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 393 4600

Website: lyratherapeutics.com

Address:

480 Arsenal Way, Watertown, United States

EF5Stocks Oct. 25 at 9:46 PM

$LYRA 10.5M market cap for a Ph3 is diabolical IMO.

0 · Reply

EF5Stocks Oct. 21 at 5:28 PM

$LYRA I believe this could be like $NERV or $RANI if they close a private placement to fund the third Phase 3 Enlighten trial. They really need to look for private equity to fund it or perhaps a big pharma partnership.

1 · Reply

EF5Stocks Oct. 17 at 10:58 PM

$LYRA IMO 11M market cap for a biotech with a Phase 3 asset that already completed one successful trial is diabolical. How is this so undervalued?

1 · Reply

Akbigd Oct. 12 at 6:09 AM

$LYRA LYRA low float (1.12M), low OS (1.64M) biotech w/ Phase 3 asset for rhino sinusitis. Cash runway into 2026. Former runner to near 40. Market cap < 15M

1 · Reply

EF5Stocks Oct. 10 at 9:59 PM

$QNRX Like this one and $LYRA both biotech and somewhat tariff proof.

0 · Reply

EF5Stocks Oct. 10 at 6:29 PM

$LYRA Hopefully they will look for a private placement like $QNRX or $SPRB to fund the next trial. Great results from earlier Enlighten trials.

0 · Reply

EF5Stocks Oct. 10 at 5:55 PM

$LYRA 1.64M OS 1.12M Float; cash runway into 2026 w/ active Phase 3 asset. Market Cap < 15M. Undervalued. Reminds me of $SPRB

0 · Reply

Akbigd Oct. 10 at 3:35 AM

$LYRA

0 · Reply

_CircuitBreaker Oct. 9 at 10:44 PM

Keep a close watch on CMCT! $TAOP $LYRA $ASPS $PLRZ 77

0 · Reply

Akbigd Oct. 9 at 3:22 AM

$LYRA small float bio worth watching w/ Phase 3 assets and sub 15M market cap. 1.64M OS; 1.12M float

0 · Reply

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Aug 12, 2025, 4:01 PM EDT - 2 months ago

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 27, 2025, 8:00 AM EDT - 4 months ago

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 16, 2025, 4:14 PM EDT - 4 months ago

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Jun 2, 2025, 8:29 AM EDT - 5 months ago

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

May 7, 2025, 7:00 AM EDT - 6 months ago

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

May 6, 2025, 4:01 PM EDT - 6 months ago

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 8 months ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Sep 27, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 21, 2024, 9:14 AM EDT - 1 year ago

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

May 6, 2024, 7:59 AM EDT - 1 year ago

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Apr 30, 2024, 4:04 PM EDT - 1 year ago

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 28, 2024, 4:39 AM EDT - 1 year ago

3 'Buy-Rated' Biotech Stocks Under $10

ADMA GERN

Apr 26, 2024, 4:51 PM EDT - 1 year ago

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 1, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 4:01 PM EST - 2 years ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:00 AM EST - 2 years ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Oct 10, 2023, 10:56 AM EDT - 2 years ago

Lyra Therapeutics: Hold For Phase 3 Topline

Oct 9, 2023, 1:20 AM EDT - 2 years ago

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 13, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Jun 2, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 1, 2023, 7:29 AM EDT - 2 years ago

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

May 26, 2023, 7:57 AM EDT - 2 years ago

Lyra Therapeutics Announces $50.0 Million Private Placement

May 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Apr 25, 2023, 7:59 AM EDT - 2 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Apr 5, 2023, 9:04 AM EDT - 2 years ago

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Mar 29, 2023, 4:06 PM EDT - 2 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023, 7:59 AM EST - 2 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 6, 2023, 7:56 AM EST - 2 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Nov 8, 2022, 4:01 PM EST - 3 years ago

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 10, 2022, 8:00 AM EDT - 3 years ago

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Aug 29, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 9, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

May 26, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at Upcoming Investor Conferences

EF5Stocks Oct. 25 at 9:46 PM

$LYRA 10.5M market cap for a Ph3 is diabolical IMO.

0 · Reply

EF5Stocks Oct. 21 at 5:28 PM

1 · Reply

EF5Stocks Oct. 17 at 10:58 PM

$LYRA IMO 11M market cap for a biotech with a Phase 3 asset that already completed one successful trial is diabolical. How is this so undervalued?

1 · Reply

Akbigd Oct. 12 at 6:09 AM

$LYRA LYRA low float (1.12M), low OS (1.64M) biotech w/ Phase 3 asset for rhino sinusitis. Cash runway into 2026. Former runner to near 40. Market cap < 15M

1 · Reply

EF5Stocks Oct. 10 at 9:59 PM

$QNRX Like this one and $LYRA both biotech and somewhat tariff proof.

0 · Reply

EF5Stocks Oct. 10 at 6:29 PM

$LYRA Hopefully they will look for a private placement like $QNRX or $SPRB to fund the next trial. Great results from earlier Enlighten trials.

0 · Reply

EF5Stocks Oct. 10 at 5:55 PM

$LYRA 1.64M OS 1.12M Float; cash runway into 2026 w/ active Phase 3 asset. Market Cap < 15M. Undervalued. Reminds me of $SPRB

0 · Reply

Akbigd Oct. 10 at 3:35 AM

$LYRA

0 · Reply

_CircuitBreaker Oct. 9 at 10:44 PM

Keep a close watch on CMCT! $TAOP $LYRA $ASPS $PLRZ 77

0 · Reply

Akbigd Oct. 9 at 3:22 AM

$LYRA small float bio worth watching w/ Phase 3 assets and sub 15M market cap. 1.64M OS; 1.12M float

0 · Reply

EF5Stocks Oct. 8 at 5:42 PM

$LYRA interesting here prior runner from 4/5 to 38 and active assets in Phase 3 w/ market cap under 15M--look at other small float bios $SPRB $GLTO $XBIO $ATON

0 · Reply

Akbigd Oct. 8 at 5:20 PM

$LYRA

0 · Reply

WoldanStanford Oct. 8 at 11:22 AM

$LYRA

0 · Reply

TA_Kongen Oct. 7 at 10:48 PM

$ACXP $BDRX $ONCO $LYRA $SLRX Potential bio movers here. All on watch.

0 · Reply

Akbigd Oct. 6 at 7:14 PM

$LYRA low Floater 1.6mill float with 12million Market Cap. It can run for day

0 · Reply

Akbigd Oct. 6 at 7:13 PM

$LYRA about to Pump Soon, NDA Submission Soon

0 · Reply

StocktwitsNews Oct. 6 at 6:35 PM

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate $LYRA $DFAS $VTI https://stocktwits.com/news/equity/markets/lyra-therapeutics-to-conduct-one-more-trial-for-chronic-rhinosinusitis-treatment-candidate/ch6RXopR3gx

0 · Reply

kshonstocks Oct. 6 at 6:32 PM

heres one that looks promising $LYRA perceptive is top holder had gd news this morning Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission - 1 for50 split back in May

1 · Reply

Rjinvestments88 Oct. 6 at 6:25 PM

$SPRB ok had to cut 3/4 position been holding for long time for this now out using profits in a few will be 👀 $LYRA With low float and insider bought nice amount before R/S and dint sell held nice bottom around 6s may hear some big news here as well also May add to my $UNH have average 302 nice dividend play with things clearing up

0 · Reply

Rjinvestments88 Oct. 6 at 6:21 PM

$CLNN low float seems news may be coming same as for $LYRA Low float after r/s while back and has very low marketcap that looks like has alot of room to run 👀

0 · Reply

Akbigd Oct. 6 at 1:41 PM

$LYRA

0 · Reply

FrozenFib Oct. 5 at 11:01 AM

$LYRA Biotech with clinical catalyst. High short interest. Volatility compression suggests large move imminent. High risk setup.

0 · Reply

Market Cap	10.33M
Revenue (ttm)	1.53M
Net Income (ttm)	-93.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,107.19%
Debt to Equity Ratio	0.00

Volume	17,400
Avg Vol	28,564
Day's Range	N/A - N/A
Shares Out	1.65M
Stochastic %K	11%
Beta	0.11
Analysts	Hold
Price Target	$11.50